187 related articles for article (PubMed ID: 33431153)
21. Health Impact and Cost-effectiveness Assessment for the Introduction of Universal Varicella Vaccination in Switzerland.
Heininger U; Pillsbury M; Samant S; Lienert F; Guggisberg P; Gani R; O'Brien E; Pawaskar M
Pediatr Infect Dis J; 2021 Jun; 40(6):e217-e221. PubMed ID: 33872276
[TBL] [Abstract][Full Text] [Related]
22. [Varicella vaccination: scientific reasons for a different strategic approach].
Donzelli A; Demicheli V
Epidemiol Prev; 2018; 42(1):65-70. PubMed ID: 29506363
[TBL] [Abstract][Full Text] [Related]
23. Modeling the impact of one- and two-dose varicella vaccination on the epidemiology of varicella and zoster.
Brisson M; Melkonyan G; Drolet M; De Serres G; Thibeault R; De Wals P
Vaccine; 2010 Apr; 28(19):3385-97. PubMed ID: 20199763
[TBL] [Abstract][Full Text] [Related]
24. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP).
Marin M; Güris D; Chaves SS; Schmid S; Seward JF;
MMWR Recomm Rep; 2007 Jun; 56(RR-4):1-40. PubMed ID: 17585291
[TBL] [Abstract][Full Text] [Related]
25. Identifying optimal vaccination scenarios to reduce varicella zoster virus transmission and reactivation.
Bakker KM; Eisenberg MC; Woods RJ; Martinez ME
BMC Med; 2022 Oct; 20(1):387. PubMed ID: 36209074
[TBL] [Abstract][Full Text] [Related]
26. An economic analysis of the universal varicella vaccination program in the United States.
Zhou F; Ortega-Sanchez IR; Guris D; Shefer A; Lieu T; Seward JF
J Infect Dis; 2008 Mar; 197 Suppl 2():S156-64. PubMed ID: 18419391
[TBL] [Abstract][Full Text] [Related]
27. Shingles in Alberta: before and after publicly funded varicella vaccination.
Russell ML; Dover DC; Simmonds KA; Svenson LW
Vaccine; 2014 Oct; 32(47):6319-24. PubMed ID: 24099868
[TBL] [Abstract][Full Text] [Related]
28. Varicella-zoster virus: pathogenesis, incidence patterns and vaccination programs.
Gabutti G; Franchi M; Maniscalco L; Stefanati A
Minerva Pediatr; 2016 Jun; 68(3):213-25. PubMed ID: 27125440
[TBL] [Abstract][Full Text] [Related]
29. Modeling the effects of varicella vaccination programs on the incidence of chickenpox and shingles.
Schuette MC; Hethcote HW
Bull Math Biol; 1999 Nov; 61(6):1031-64. PubMed ID: 17879870
[TBL] [Abstract][Full Text] [Related]
30. Early impact of universal varicella vaccination on childhood varicella and herpes zoster hospitalizations in Brazil.
Scotta MC; Paternina-de la Ossa R; Lumertz MS; Jones MH; Mattiello R; Pinto LA
Vaccine; 2018 Jan; 36(2):280-284. PubMed ID: 29198917
[TBL] [Abstract][Full Text] [Related]
31. The cost-effectiveness of routine childhood varicella vaccination in Germany.
Banz K; Wagenpfeil S; Neiss A; Goertz A; Staginnus U; Vollmar J; Wutzler P
Vaccine; 2003 Mar; 21(11-12):1256-67. PubMed ID: 12559807
[TBL] [Abstract][Full Text] [Related]
32. Review of the United States universal varicella vaccination program: Herpes zoster incidence rates, cost-effectiveness, and vaccine efficacy based primarily on the Antelope Valley Varicella Active Surveillance Project data.
Goldman GS; King PG
Vaccine; 2013 Mar; 31(13):1680-94. PubMed ID: 22659447
[TBL] [Abstract][Full Text] [Related]
33. Universal mass vaccination against varicella in Germany using an MMRV combination vaccine with a two-dose schedule: an economic analysis.
Hammerschmidt T; Bisanz H; Wutzler P
Vaccine; 2007 Oct; 25(42):7307-12. PubMed ID: 17881097
[TBL] [Abstract][Full Text] [Related]
34. The case against universal varicella vaccination.
Goldman GS
Int J Toxicol; 2006; 25(5):313-7. PubMed ID: 16940003
[TBL] [Abstract][Full Text] [Related]
35. Global impact of varicella vaccination programs.
Varela FH; Pinto LA; Scotta MC
Hum Vaccin Immunother; 2019; 15(3):645-657. PubMed ID: 30427766
[TBL] [Abstract][Full Text] [Related]
36. Economic burden of varicella in Singapore--a cost benefit estimate of implementation of a routine varicella vaccination.
Jean-Jasmin LM; Lynette SP; Stefan M; Kai CS; Chew FT; Wah LB
Southeast Asian J Trop Med Public Health; 2004 Sep; 35(3):693-6. PubMed ID: 15689089
[TBL] [Abstract][Full Text] [Related]
37. Modelling the impact of a combined varicella and zoster vaccination programme on the epidemiology of varicella zoster virus in England.
van Hoek AJ; Melegaro A; Zagheni E; Edmunds WJ; Gay N
Vaccine; 2011 Mar; 29(13):2411-20. PubMed ID: 21277405
[TBL] [Abstract][Full Text] [Related]
38. Assessing the impact of chickenpox and shingles vaccination using intermittent enhanced surveillance in Queensland, Australia.
Shrestha AC; Field E; Rajmokan M; Lambert SB
Vaccine; 2023 Dec; 41(50):7539-7547. PubMed ID: 37980260
[TBL] [Abstract][Full Text] [Related]
39. Modeling the impact of combined vaccination programs against varicella and herpes zoster in Norway.
Marchetti S; Guzzetta G; Flem E; Mirinaviciute G; Scalia Tomba G; Manfredi P
Vaccine; 2018 Feb; 36(8):1116-1125. PubMed ID: 29366704
[TBL] [Abstract][Full Text] [Related]
40. Cost effectiveness of vaccination strategies in adults without a history of chickenpox.
Smith KJ; Roberts MS
Am J Med; 2000 Jun; 108(9):723-9. PubMed ID: 10924649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
